Laura Mulloy, DO
Nephrology · Augusta, GANPI 1376652388
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by GSK at 50.9% of the total. Reporting peaked in 2022 at $4,712 and has fallen 84.3% since, to $740 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $54.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- Cipla USA Inc.$1K
- AstraZeneca$852
- Vifor Pharma, Inc.$376
- Otsuka America Pharmaceutical, Inc.$277
- Mallinckrodt Hospital Products Inc.$269
- plus $2K from 27 others
Across 123 payments — averaging $7154.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$524K
- Vertex$245K
- Aurinia Pharma U.S., Inc.$40K
- E.r. Squibb & Sons, L.L.C.$39K
- Bayer$33K
What the payments were for
- Consulting fees$3,68035%
- Travel & lodging$1,14211%
- Food & beverage$5,37051%
- Education$3373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 20 | $5,364 |
| Cipla USA Inc. | 2 | $1,035 |
| AstraZeneca(2 entities) | 43 | $852 |
| Vifor Pharma, Inc. | 15 | $376 |
| Otsuka America Pharmaceutical, Inc. | 8 | $277 |
| Mallinckrodt Hospital Products Inc. | 9 | $269 |
| Amgen | 9 | $234 |
| Fresenius USA Marketing, Inc. | 11 | $209 |
| Calliditas Therapeutics US Inc. | 4 | $197 |
| Travere Therapeutics, Inc. | 9 | $189 |
| OPKO Pharmaceuticals, LLC | 7 | $152 |
| Astellas Pharma US Inc | 4 | $126 |
| Renalytix AI, Inc. | 5 | $122 |
| Aurinia Pharma U.S., Inc. | 6 | $120 |
| Veloxis Pharmaceuticals, Inc. | 5 | $120 |
| Mallinckrodt Enterprises LLC | 2 | $111 |
| Ardelyx, Inc. | 4 | $91 |
| Bayer | 5 | $83 |
| La Jolla Pharmaceutical Company | 1 | $77 |
| Merck | 3 | $70 |
| Novartis | 3 | $66 |
| Akebia Therapeutics Inc | 3 | $64 |
| Vertex | 1 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Melinta Therapeutics, LLC | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Amicus Therapeutics, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEMDRI (PLAZOMICIN)$1,035
- TARPEYO$121
How this compares
$10,529 in reported general payments places this provider in the 90th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 16 | $51,609 |
| KerendiaFinerenone | 35 | $26,677 |
| JardianceEmpagliflozin | 32 | $23,125 |
| FarxigaDapagliflozin Propanediol | 20 | $20,754 |
| OzempicSemaglutide | 17 | $15,397 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $14,111 |
| Valganciclovir Hcl | 53 | $10,803 |
| Sevelamer Carbonate | 53 | $10,618 |
| JanuviaSitagliptin Phosphate | 14 | $7,788 |
| EliquisApixaban | 11 | $7,505 |
| Cinacalcet Hcl | 29 | $5,983 |
| Levemir FlexpenInsulin Detemir | 11 | $2,242 |
| Calcium Acetate | 15 | $1,373 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,005 |
| Labetalol Hcl | 21 | $814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $64 | $51,60916 claims |
| AstraZenecaFarxiga, Lokelma | $852 | $34,86535 claims |
| BayerKerendia | $83 | $26,67735 claims |
| MerckJanuvia | $70 | $7,78814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 nephrology providers in Georgia.
Other nephrology in Augusta
- Don WilliamsonAugusta$104K
- Barton BrezinaAugusta$47K
- Matthew DiamondAugusta$14K
- Syed BabarAugusta$8K
- Muralidharan JagadeesanAugusta$8K
- Shameem BeighAugusta$7K
- Harold HubertAugusta$7K
- Devesh PatelAugusta$6K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.